Skip to main content
Top
Gepubliceerd in: TPO - De Praktijk 1/2013

01-02-2013 | Beschouwing

Zin en onzin van scherp instellen glucosegehalte

Auteur: Guy Rutten

Gepubliceerd in: TvPO | Uitgave 1/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De afgelopen vijf jaar zijn onze inzichten over de effecten van hyperglykemiebehandeling aanmerkelijk veranderd. Intensieve verlaging van het HbA1c verlaagt de sterfte niet, wel de kans op microvasculaire complicaties (die overigens pas in de loop van heel wat jaren ontstaan). Het blijft twijfelachtig of er een gunstig effect is op niet-fatale hartinfarcten. En intensivering van de behandeling leidt wel tot significant meer hypo’s. Volgens recente internationale richtlijnen is het daarom raadzaam om bij het instellen van de glucosewaarden behalve met levensverwachting, psychosociale factoren en comorbiditeit ook rekening te houden met het risico op hypo’s, de diabetesduur, het al bestaan van hart- en vaatziekten en de kosten van behandeling. De nieuwe NHG-Standaard Diabetes mellitus zal dat ook gaan doen. Voor sommige patiënten met diabetes type 2 zullen we daarom ons beleid moeten bijstellen.
Literatuur
1.
go back to reference Stone MA, Charpentier G, Doggen G, Rutten GE, et al. Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE ) study. Diab Care 2013, in press. Stone MA, Charpentier G, Doggen G, Rutten GE, et al. Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE ) study. Diab Care 2013, in press.
2.
go back to reference UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352;837-53.CrossRef UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352;837-53.CrossRef
3.
go back to reference UK Prospective Diabetes Study Group. Effect of intensive bloodglucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854- 65.CrossRef UK Prospective Diabetes Study Group. Effect of intensive bloodglucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854- 65.CrossRef
4.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.PubMedCrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.PubMedCrossRef
5.
go back to reference Rutten GE, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K, et al. NHG -Standaard Diabetes mellitus type (Eerste herziening). Huisarts Wet 1999;42:67-84. Rutten GE, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K, et al. NHG -Standaard Diabetes mellitus type (Eerste herziening). Huisarts Wet 1999;42:67-84.
6.
go back to reference Rutten GEHM, De Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van Der Does FEE, et al. NHG –Standaard Diabetes mellitus type 2 (Tweede herziening). www.nhg.orgwww.nhg.org Rutten GEHM, De Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van Der Does FEE, et al. NHG –Standaard Diabetes mellitus type 2 (Tweede herziening). www.​nhg.​orgwww.nhg.org
7.
go back to reference Holman R, Sanjoy P, Bethel A, Mattews D, et al. 10-Year followup of intensive glucose control in type 2 diabetes. N Eng J Med 2008;359:1577-89.CrossRef Holman R, Sanjoy P, Bethel A, Mattews D, et al. 10-Year followup of intensive glucose control in type 2 diabetes. N Eng J Med 2008;359:1577-89.CrossRef
8.
go back to reference Griffin SJ, Borch-Johnsen K, Davies M, Rutten GE, et al. Effect of early intensive multifactorial therapy on 5-yearcardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION Europe). Lancet 2011;378:156-67.PubMedCrossRef Griffin SJ, Borch-Johnsen K, Davies M, Rutten GE, et al. Effect of early intensive multifactorial therapy on 5-yearcardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION Europe). Lancet 2011;378:156-67.PubMedCrossRef
9.
go back to reference The ACCO RD Study Group. Effects of intensive blood glucose lowering in type 2 diabetes. N Eng J Med 2008;358:2545-59.CrossRef The ACCO RD Study Group. Effects of intensive blood glucose lowering in type 2 diabetes. N Eng J Med 2008;358:2545-59.CrossRef
10.
go back to reference The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008;358:2560-72.CrossRef The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008;358:2560-72.CrossRef
11.
go back to reference Duckworth W, Abreira C, Moritz T, Reda D, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Eng J Med 2009;360:129-39.CrossRef Duckworth W, Abreira C, Moritz T, Reda D, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Eng J Med 2009;360:129-39.CrossRef
12.
go back to reference Currie CJ, Peters J, Aodan T, Evans M, et al. Survival as function of HbA1c in people with type 2 diabetes: A retrospective cohort study. Lancet 2010;375:481-9.PubMedCrossRef Currie CJ, Peters J, Aodan T, Evans M, et al. Survival as function of HbA1c in people with type 2 diabetes: A retrospective cohort study. Lancet 2010;375:481-9.PubMedCrossRef
13.
go back to reference Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.CrossRef Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.CrossRef
14.
go back to reference Hemmingsen B, Lund S, Gluud C, Vaag A, et al. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trila sequential analysis of randomised clinical trials. BMJ 2011;343:d6898.CrossRef Hemmingsen B, Lund S, Gluud C, Vaag A, et al. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trila sequential analysis of randomised clinical trials. BMJ 2011;343:d6898.CrossRef
15.
go back to reference Van Avendonk MJP, Rutten GEHM. Insulin therapy in type 2 diabetes: What is the evidence? Diabetes Obes Metab 2009; 11;415-32.PubMedCrossRef Van Avendonk MJP, Rutten GEHM. Insulin therapy in type 2 diabetes: What is the evidence? Diabetes Obes Metab 2009; 11;415-32.PubMedCrossRef
16.
go back to reference Inzuccchi SE , Bergenstahl RM, Buse JB, Diamant M, et al. Management of hyperglycaemia in type 2 diabetes: A patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577-96CrossRef Inzuccchi SE , Bergenstahl RM, Buse JB, Diamant M, et al. Management of hyperglycaemia in type 2 diabetes: A patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577-96CrossRef
Metagegevens
Titel
Zin en onzin van scherp instellen glucosegehalte
Auteur
Guy Rutten
Publicatiedatum
01-02-2013
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
TvPO / Uitgave 1/2013
Print ISSN: 2666-9838
Elektronisch ISSN: 2666-9846
DOI
https://doi.org/10.1007/s12503-013-0010-z

Andere artikelen Uitgave 1/2013

TPO - De Praktijk 1/2013 Naar de uitgave

Redactioneel

Oud & nieuw